Canaccord Genuity Reiterates a 'Buy' on Zalicus (ZLCS); Q1 Update: Synavive Phase 2b Enrollment Complete
Tweet Send to a FriendGet Alerts ZLCS Hot Sheet
Price: $0.60 -3.23%
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ZLCS Now!
Canaccord Genuity reiterates a 'Buy' on Zalicus (NASDAQ: ZLCS) price target of $3.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker."
For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.
Shares of Zalicus closed at $0.84 yesterday, with a 52 week range of $0.82-$2.90.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker."
For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.
Shares of Zalicus closed at $0.84 yesterday, with a 52 week range of $0.82-$2.90.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Needham & Company Remains on Sidelines wth Applied Materials (AMAT) Post Q2
- Wells Fargo Upgrades Rosetta Resources (ROSE) to Outperform, Shares Attractive
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
